GLENMARK PHARMACEUTICALS EUROPE LIMITED

DCGI declares 16 commonly-used medicines, including Glenmark’s Telma H and Sun Pharma’s Ursocol 300, as spurious after failing quality and safety tests. Over 300 actions taken against manufacturers in the last year, with 3,053 substandard and 424 spurious drugs found in 2022-23.

KIIT School of Biotechnology hosted the 10th Biotech Industrial Conclave on 'Biotechnology for Humanity: Innovations Shaping a Better World' on August 23-24, 2024, featuring discussions on industry-academia collaboration, emerging trends in biotech, and the role of startups. Key speakers included Dr. Achyuta Samanta, Dr. Krishna Ella, and various industry experts, focusing on topics like vaccine development, molecular diagnostics, and food safety.

India's drug formulations market to grow at 9-10% CAGR over the next decade, with Jan Aushadhi outlets expected to contribute 30% to market volume. Branded generics to remain dominant, growing at over 8% CAGR. Glenmark has 52 product applications pending in North America and awaits approval for four respiratory products in Europe.

Glenmark predicts India's drug formulations market to grow at 9-10% CAGR over the next decade, with Jan Aushadhi outlets expected to contribute 30% of market volume in ten years. Despite this, branded generics are anticipated to remain dominant, comprising 65-70% of the market by value.